New Releases from NCBI BookshelfLutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours.Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours.

By admin / December 18, 2025

Post Content

New Releases from NCBI BookshelfOcrelizumab for treating relapsing–remitting multiple sclerosis.Ocrelizumab for treating relapsing–remitting multiple sclerosis.

New Releases from NCBI BookshelfMirikizumab (Omvoh): Indication: For the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, loss of response, or were intolerant to either conventional therapy or a biologic treatment: Reimbursement Recommendation [Internet].Mirikizumab (Omvoh): Indication: For the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, loss of response, or were intolerant to either conventional therapy or a biologic treatment: Reimbursement Recommendation [Internet].

Useful Links

NEWREDMARS SKILL AND RESEARCH FOUNDATION

Registration No: 771800548 Contact Number : +91-8249516996

Publication
Skill Development
Blog Writing

Research
Awareness Camp
Digital Research

Ngo Darpan
Service
Donation

Term and Condition
Privacy Policy
Disclaimer

Scroll to Top

New Releases from NCBI BookshelfLutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours.Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours.

Leave a Comment Cancel Reply

Useful Links

NEWREDMARS SKILL AND RESEARCH FOUNDATION

©2021-2024. Newredmars Skill and Research Foundation. All Rights Reserved.